Active immunotherapy of cancer for minimal residual disease: new trends and new materials.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007109:Immunity; D007167:Immunotherapy; D007978:Levamisole / Q000627:therapeutic use; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000628:therapy
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D001500:BCG Vaccine; D007978:Levamisole